Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer

NCT03288545 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT03288545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
October 11, 2017
Completion date
February 20, 2026
Enrollment
348 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, transitional cell, renal pelvis neoplasms, ureteral neoplasms, urethral neoplasms, urinary bladder neoplasms, urologic neoplasms, urothelial cancer